TWiV 1076: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin highlights global circulation of Mpox virus, reviews the most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, and discusses the clinical outcome of hospitalized children under 5 years infected with SARS-CoV-2, the perinatal and neonatal outcomes including adverse effects of SARS-CoV-2 infection and virus transmission in Italy between early 2020 and 2022, the guidelines to improve home ventilation, the safety and efficacy of the oral anti-viral molnupiravir and the use of convalescent plasma as a long term treatment as well as treatment specifically for the immune compromised, the ineffectiveness of antibiotics for treating COVID-19, the association of olfactory dysfunction and the administration of corticosteroids and the safety of the RSV vaccines licensed last year.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Articles and graphs cited in TWIV CU 1076
• Global mpox circulation (WHO)
• Mpox in the Americas and Europe (CIDRAP)
• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC)
• RSV national trend (CDC)
• Influenza/flu surveillance  (CDC)
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot)
• Vaccine-Eligible Children Under-5 Years (PIDJ)
• Pre-school cohort vaccination rate (CIDRAP)
• Perinatal transmission and neonatal outcomes (IJID)
• Adverse maternal and neonatal effect (dgalerts)
• Ventilation home improvements (CDC)
• Quarantine/isolation guidelines (CDC)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma remmendation for immunocompromised (IDSociety)
• Corticosteroids in SARS-CoV-2
• Anticoagulation guidelines (hematology.org)
• Corticosteroids induced olfactory dysfunction (PLoS One)
• Convalescent Plasma Therapy: Long Term Implications (OFID)
• Preventing RSV infection by vaccination (MMWR)
• Antivirals and chronic kidney disease (CID) Early administraton of molnupiravir versus ritonavir-boosted nirmatrelvir (Lancet Infectious Diseases)
• Contribute to our MicrobeTV fundraiser at PWB
• Letters read on TWiV 1076
• Dr. Griffin's COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]